ENTERA BIO LTD. Increase (Decrease) in Accounts Receivable
ENTERA BIO LTD. (ENTX) reported Increase (Decrease) in Accounts Receivable of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-07
- ENTERA BIO LTD. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $0.00.
- ENTERA BIO LTD. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- ENTERA BIO LTD. increase (decrease) in accounts receivable for the quarter ending 2024-12-31 was -$7.00K.
- ENTERA BIO LTD. increase (decrease) in accounts receivable for the quarter ending 2024-09-30 was $76.00K.
- ENTERA BIO LTD. increase (decrease) in accounts receivable for fiscal 2025 was -$126.00K, a 200.00% decline from fiscal 2024.
- ENTERA BIO LTD. increase (decrease) in accounts receivable for fiscal 2024 was $126.00K.
- ENTERA BIO LTD. increase (decrease) in accounts receivable for fiscal 2023 was -$246.00K, a 490.48% decline from fiscal 2022.
- ENTERA BIO LTD. increase (decrease) in accounts receivable for fiscal 2022 was $63.00K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 9 month as first filed | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-07 | ||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $0.00 derived: sum of 2 quarters · filed 2026-03-27 | -$126.00K 10-K · filed 2026-03-27 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$126.00K 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | -$126.00K 10-Q · filed 2026-08-07 | ||||
| 2024-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $69.00K derived: sum of 2 quarters · filed 2026-03-27 | $126.00K derived: sum of 3 quarters · filed 2026-03-27 | $126.00K 10-K · filed 2026-03-27 | |
| 2024-09-30 | $76.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $133.00K derived: sum of 2 quarters · filed 2025-11-14 | $133.00K 10-Q · filed 2025-11-14 | $42.00K 10-Q · filed 2024-11-08 | $133.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $57.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $57.00K 10-Q · filed 2025-08-08 | $57.00K derived: sum of 3 quarters · filed 2025-08-08 | $28.00K derived: sum of 4 quarters · filed 2025-08-08 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-10 | $0.00 derived: sum of 2 quarters · filed 2025-03-28 | -$29.00K derived: sum of 3 quarters · filed 2025-03-28 | -$29.00K derived: sum of 4 quarters · filed 2025-03-28 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$29.00K derived: sum of 2 quarters · filed 2025-03-28 | -$29.00K derived: sum of 3 quarters · filed 2025-03-28 | -$246.00K 10-K · filed 2025-03-28 | |
| 2023-09-30 | -$29.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$29.00K derived: sum of 2 quarters · filed 2024-11-08 | -$246.00K 10-Q · filed 2024-11-08 | -$233.00K derived: sum of 4 quarters · filed 2024-11-08 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$217.00K 10-Q · filed 2024-08-09 | -$204.00K derived: sum of 3 quarters · filed 2024-08-09 | -$196.00K derived: sum of 4 quarters · filed 2024-08-09 | |
| 2023-03-31 | -$217.00K 10-Q · filed 2024-05-10 | -$204.00K derived: sum of 2 quarters · filed 2024-05-10 | -$196.00K derived: sum of 3 quarters · filed 2024-05-10 | -$181.00K derived: sum of 4 quarters · filed 2024-05-10 | |
| 2022-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $21.00K derived: sum of 2 quarters · filed 2024-03-08 | $36.00K derived: sum of 3 quarters · filed 2024-03-08 | $63.00K 10-K · filed 2024-03-08 | |
| 2022-09-30 | $8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $23.00K derived: sum of 2 quarters · filed 2023-11-14 | $50.00K 10-Q · filed 2023-11-14 | -$19.00K derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $42.00K 10-Q · filed 2023-08-11 | -$27.00K derived: sum of 3 quarters · filed 2023-08-11 | $109.00K derived: sum of 4 quarters · filed 2023-08-11 | |
| 2022-03-31 | $27.00K 10-Q · filed 2023-05-05 | -$42.00K derived: sum of 2 quarters · filed 2023-05-05 | $94.00K derived: sum of 3 quarters · filed 2023-05-05 | $195.00K derived: sum of 4 quarters · filed 2023-05-05 | |
| 2021-12-31 | -$69.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $67.00K derived: sum of 2 quarters · filed 2023-03-31 | $168.00K derived: sum of 3 quarters · filed 2023-03-31 | -$72.00K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $136.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $237.00K derived: sum of 2 quarters · filed 2022-11-10 | -$3.00K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $101.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$139.00K 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | -$240.00K 10-Q · filed 2022-05-12 | ||||
| 2020-12-31 | -$23.00K 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |